苯并咪达韦

苯并咪达韦（CAS 176161-24-3）的独立参考数据，整理自公开化学数据库。

各数据库的登记标识

计算分子描述符

在册的记载用途

Maribavir is indicated for the treatment of post-transplant cytomegalovirus (CMV) infection (following hematopoietic stem cell transplant or solid organ transplant) which is refractory to standard treatment with [ganciclovir], [valganciclovir], [cidofovir], or [foscarnet]. In the US, patients receiving the treatment should weigh more than 35 kg and be at least 12 years old. In Canada and Europe, maribavir is only approved in adults.Maribavir is an orally available, antiviral agent which inhibits the pUL97 kinase of cytomegalovirus (CMV) and is used to treat refractory forms of post-transplant CMV infection. Maribavir has been associated with low rates of mild-to-moderate serum aminotransferase elevations during therapy but has not been linked to cases of clinically apparent acute liver injury.

同义词与商品名

Maribavir; 176161-24-3; Benzimidavir; livtencity; 1263W94; Camvia; maribavirum; BW-1263W94; GW-257406X; (2S,3S,4R,5S)-2-[5,6-dichloro-2-(propan-2-ylamino)benzimidazol-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol; GW-1263; PTB4X93HE1; BW 1263W94; 1263-W-94; DTXSID60170091; GW257406X

GHS 危害分类

Reported hazard statements	H302 (100%), H318 (50%), H371 (50%)

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

H318 (50%): Causes serious eye damage [Danger Serious eye damage/eye irritation]

公开数据库对它的描述

BENZIMIDAVIR · CAS 176161-24-3 · C15H19Cl2N3O4. UNII PTB4X93HE1.

数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。